Purple Biotech (PPBT) Projected to Post Earnings on Saturday

Purple Biotech (NASDAQ:PPBT) is expected to be posting its Q1 2026 results before the market opens on Saturday, May 16th. Analysts expect Purple Biotech to post earnings of ($0.38) per share for the quarter.

Purple Biotech (NASDAQ:PPBT) last released its quarterly earnings data on Friday, March 13th. The company reported ($19.85) EPS for the quarter, missing analysts’ consensus estimates of ($3.40) by ($16.45). On average, analysts expect Purple Biotech to post $-17 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Purple Biotech Trading Up 7.5%

NASDAQ:PPBT traded up $0.28 during trading hours on Friday, hitting $3.97. The company had a trading volume of 11,883 shares, compared to its average volume of 12,305. The company has a 50-day moving average of $4.21 and a 200 day moving average of $5.96. The company has a market cap of $5.10 million, a P/E ratio of -0.19 and a beta of 0.68. Purple Biotech has a 1 year low of $3.49 and a 1 year high of $29.00.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Weiss Ratings lowered shares of Purple Biotech from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, May 4th. HC Wainwright dropped their target price on shares of Purple Biotech from $34.00 to $30.00 and set a “buy” rating for the company in a report on Friday, March 13th. Finally, Zacks Research raised shares of Purple Biotech from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $30.00.

Institutional Trading of Purple Biotech

An institutional investor recently bought a new position in Purple Biotech stock. SmartHarvest Portfolios LLC purchased a new stake in shares of Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 47,454 shares of the company’s stock, valued at approximately $31,000. SmartHarvest Portfolios LLC owned approximately 0.37% of Purple Biotech at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.64% of the company’s stock.

About Purple Biotech

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage.